{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:03:06Z","timestamp":1790053386127,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) is a chronic inflammatory bowel disease with rising global prevalence. Biologic agents have become the cornerstone of treatment for moderate-to-severe CD, yet the rapidly expanding literature makes systematic tracking of research trends challenging. This study presents a comprehensive bibliometric analysis to systematically map the research landscape of biologic therapy for CD from 2015 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications on biologic therapy for CD were retrieved from the PubMed, Web of Science Core Collection, and Scopus databases for the period from 1 January 2015 to 31 December 2025. To ensure consistency in interpretation and indexing across databases, only English-language articles were included. After deduplication using EndNote and manual screening, 15,828 eligible publications were included in the final analysis. Bibliometric and visualization analyses were performed using CiteSpace, VOSviewer, RStudio, and SCImago Graphica. Metrics including annual publication output, country contributions with centrality analysis (indicating a country\u2019s bridging role in international collaboration networks), institutional collaboration networks, author co-authorship patterns, keyword co-occurrence, cluster analysis, timeline visualization, and citation bursts were systematically examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The annual publication output showed a consistent upward trend. The United States (n = 4,505), China (n = 1,528), and Italy (n = 1,509) were the top three producers; Canada showed the highest centrality (0.93), reflecting its role as a key bridge in transnational collaborations. Keyword co-occurrence revealed a trilevel structure centered on CD, with \u201cbiological marker\u201d and \u201cbiological product\u201d appearing at near-equal frequencies. Eleven clusters were identified (Q = 0.5991, silhouette = 0.8053), and 25 citation bursts revealed a three-phase evolution from efficacy validation to strategy optimization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The bibliometric findings demonstrate that CD biologic therapy research has established a mature ecosystem, with shifting emphases toward biomarker-driven stratification and comparative effectiveness. Future priorities emerging from the data include individualized sequencing strategies, head-to-head comparisons with novel small-molecule agents, and expanded investigation in understudied populations such as adolescents and pregnant women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1943640","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:14Z","timestamp":1790050934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic therapy for Crohn\u2019s disease (2015\u20132025): a bibliometric analysis of global research trends and current status"],"prefix":"10.3389","volume":"17","author":[{"given":"Pengfei","family":"Zhou","sequence":"first","affiliation":[{"name":"Anorectal Department, The First Affiliated Hospital of Henan University of CM","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[{"name":"Anorectal Department, The First Affiliated Hospital of Henan University of CM","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manxiang","family":"Wei","sequence":"additional","affiliation":[{"name":"Anorectal Department, The First Affiliated Hospital of Henan University of CM","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Anorectal Department, The First Affiliated Hospital of Henan University of CM","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Qu","sequence":"additional","affiliation":[{"name":"Anorectal Department, The First Affiliated Hospital of Henan University of CM","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[{"name":"Coloproctology Department, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Second People\u2019s Hospital Affiliated to Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD003574","DOI":"10.1002\/14651858","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","volume":"2003","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s10620-020-06212-7","article-title":"Vedolizumab (VDZ) for UC and CD: still safe and effective after all these years","volume":"65","author":"Bach","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"28","author":"D'Haens","year":"2022","journal-title":"Lancet. May"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's Disease","volume":"17","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1093\/ecco-jcc\/jjad098","article-title":"Gut microbiome-generated phenylacetylglutamine from dietary protein is associated with Crohn's Disease and exacerbates Colitis in mouse model possibly via platelet activation","volume":"17","author":"Feng","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"28","author":"Ferrante","year":"2022","journal-title":"Lancet. May"},{"key":"B11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/s1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2036.2007.03583.x","article-title":"The use of adalimumab in the management of refractory Crohn's disease","volume":"27","author":"Ho","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","article-title":"The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's Disease: results from the SUCCESS consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1586\/17474124.1.1.29","article-title":"Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease","volume":"1","author":"Ko","year":"2007","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in Crohn's Disease but not in ulcerative colitis: systematic review and meta-analysis","volume":"30","author":"Law","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"Cd007572","DOI":"10.1002\/14651858.CD007572.pub3","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","volume":"25","author":"MacDonald","year":"2016","journal-title":"Cochrane Database Syst. Rev. Nov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's Disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/ibd.22973","article-title":"Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials","volume":"18","author":"Roth","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune System","volume":"12","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci. Jan."},{"key":"B25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's Disease in patients Na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1007\/s10620-021-07361-z","article-title":"Influence of corticosteroid use on Short- and long-term outcomes of biologic therapy for inflammatory bowel diseases","volume":"67","author":"Sieber","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risks and benefits of infliximab for the treatment of Crohn's disease","volume":"4","author":"Siegel","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/11312710-000000000-00000","article-title":"Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease","volume":"27","author":"Yu","year":"2009","journal-title":"Pharmacoeconomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1943640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:14Z","timestamp":1790050934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1943640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1943640"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1943640","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1943640"}}